- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01690312
Clinical Study to Assess High-DHA Fish Oil on Biomarkers of Cardiovascular Disease Risk in Adults on Statin Therapy
Clinical Study to Assess the Acute and Chronic Effects of a High-DHA Fish Oil on Fasting and Post-Prandial Biomarkers of Cardiovascular Disease Risk in Adults on Statin Therapy.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This study involves fasted and post-prandial components.
Fasted Study:
Participants will provide fasting blood samples pre-and post-intervention [4-week administration of supplement or placebo] in Treatment Period I. Participants will again provide fasting blood samples pre-and post-intervention [4-week administration of supplement or placebo, opposite to Treatment Period I] during Treatment Period II.
There will be a 4-week washout period during the two Treatment Periods.
Post-prandial study:
Participants will also complete a post-prandial study pre-and post-intervention during each Treatment Period.
Tipo de estudo
Inscrição (Antecipado)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Ontario
-
Guelph, Ontario, Canadá, N1G 0B4
- Nutrasource Diagnostics Inc.
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Be an adult between the ages of 18 and 70;
- Be a male or a post-menopausal female who has gone a minimum of one year since their last menses;
- Be taking Statin medication at a stable dose for a minimum of four weeks prior to study commencement [and whom have reached a target LDL level];
- Have elevated fasting triglyceride levels [greater than 1.5 mmol/L but less than 5.7 mmol/L];
- Have fasting blood glucose levels below the study cut-off [less than 7.0 mmol/L];
- Have a Body Mass Index (BMI) less than 35.0
- Be taking natural health products BUT agree to cease consumption during the study period and a 4-week pre-study washout prior to study commencement. Study participants will be allowed to consume a daily multivitamin if they have been doing so at a stable dose for a minimum of three months prior to study commencement.
Exclusion Criteria:
- Be younger than 18 years of age or older than 70 years of age;
- Be an adult pre- or peri-menopausal female;
- Not have taken Statin medication at a stable dose for a minimum of 4 weeks prior to study commencement;
- Have fasting triglyceride levels outside of study limits[ie/ less than 1.5 mmol/L or greater than 5.7 mmol/L];
- Have elevated fasting blood glucose levels [greater or equal to 7.0 mmol/L];
- Have high blood pressure [greater than 140/100]
- Have a Body Mass Index (BMI) equal to or greater than 35.0
- Have a pre-existing cardiovascular disease or illness, including angina, myocardial infarction, stroke, intermittent claudication or transient ischemic attack;
- Have a known allergy to fish and/or fish oil, olive oil, soy or Vitamin E;
- Be taking natural health products but are unwilling to cease consumption during the study period and a 4-week pre-study washout prior to study commencement;
- Consume more than two (2) fish meals on a weekly basis
- Consume excessive amounts of alcohol on a weekly basis [more than 10 alcoholic drinks per week];
- Anticipate or have planned surgery during the course of the study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: 1 (Dietary Supplement - Fish Oil)
On Day 1 & Day 29, the researcher will obtain anthropometric measurements as specified in the study protocol. A venous catheter will be inserted and a fasted blood sample will be drawn, which will be analyzed for study primary and secondary endpoints. Participants will consume a Breakfast Meal (which will represent t0) and will have blood drawn at a total of 7 time points. Blood samples drawn at30, t60, t120, and t180 will be analyzed for glucose and insulin; blood samples drawn at t60, t120, t180, t240, t300 and t360 will be analyzed for triglycerides. Upon completion of the 6 hour blood draw period, the venous catheter will be removed. On Day 15, the researcher will obtain anthropometric measurements as specified in the study protocol. |
On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day.
Each capsule contains 1000 mg of fish oil [620 mg of DHA and 150 mg of EPA], providing a total daily dosage of 4000 mg of fish oil [3080 mg of DHA+EPA].
|
|
Experimental: 2 (Placebo)
On Day 1 & Day 29, the researcher will obtain anthropometric measurements as specified in the study protocol. A venous catheter will be inserted and a fasted blood sample will be drawn, which will be analyzed for study primary and secondary endpoints. Participants will consume a Breakfast Meal (which will represent t0) and will have blood drawn at a total of 7 time points. Blood samples drawn at30, t60, t120, and t180 will be analyzed for glucose and insulin; blood samples drawn at t60, t120, t180, t240, t300 and t360 will be analyzed for triglycerides. Upon completion of the 6 hour blood draw period, the venous catheter will be removed. On Day 15, the researcher will obtain anthropometric measurements as specified in the study protocol. |
On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day.
Each capsule contains 1000 mg of olive oil, providing a total daily dosage of 4000 mg of olive oil.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Triglyceride [TG]
Prazo: 0 and 4 weeks
|
Fasted and postprandial samples will be drawn (hourly up to 6 hours).
|
0 and 4 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Glucose
Prazo: 0 and 4 weeks
|
Fasted and postprandial samples will be drawn (every 30 minutes up to 2 hours).
|
0 and 4 weeks
|
|
Insulin
Prazo: 0 and 4 weeks
|
Fasted and postprandial samples will be drawn (every 30 minutes up to 2 hours).
|
0 and 4 weeks
|
|
Total cholesterol [TC]
Prazo: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
High-density lipoprotein [HDL]
Prazo: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Low-density lipoprotein [LDL]
Prazo: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Very low-density lipoprotein [VLDL]
Prazo: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Lipoprotein A
Prazo: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Intermediate-density lipoprotein [IDL]
Prazo: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Remnant Lipoproteins
Prazo: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
High-sensitivity C-Reactive Protein [hs-CRP]
Prazo: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Homocysteine
Prazo: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Essential Fatty Acid Profile
Prazo: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Apolipoprotein B
Prazo: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Apolipoprotein A-1
Prazo: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
Colaboradores e Investigadores
Investigadores
- Investigador principal: Alison Duncan, Ph.D., R.D., University of Guelph
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
- Insulina
- Humanos
- Doença cardiovascular
- DHA
- Óleo de peixe
- Estatinas
- Glicose
- Triglicerídeos
- Pós-prandial
- Homocisteína
- EPA
- Lipoproteínas
- Jejum
- Apolipoproteína B
- High-DHA
- Total cholesterol [TC]
- High-density lipoprotein [HDL2, HDL3]
- Low-density lipoprotein [LDL1+2+3+4]
- Lipoprotein A [Lp(a)]
- Intermediate-density lipoprotein (IDL)
- Very low-density lipoprotein (VLDL1+2, VLDL3)
- Remnant Lipoproteins
- High-sensitivity C-Reactive Protein [hs-CRP]
- Essential Fatty Acid Profile
- Apolipoprotein A-1
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 11-09-002
- 150038 (Health Canada)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .